Teva Pharmaceutical Industries Limited (TEVA)
After hours:
- Business Wire
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)
AMSTERDAM, June 24, 2022--Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria.
- Motley Fool
Nasdaq Bear Market: 3 of the Cheapest Stocks You Can Confidently Buy Right Now
These highly profitable stocks are valued at just three to six times Wall Street's forecast earnings for 2023.
- Business Wire
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
TEL AVIV, Israel & PARSIPPANY, N.J., June 09, 2022--Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s Abbreviated New Drug Application ("ANDA") for a generic deutetrabenazine product. Teva and Aurobindo have been involved in a patent infringement litigation in which Teva asserted a number of patents against A
